Learn about BYETTA, the BYETTA Pen. Important Safety Information for BYETTA (exenatide) injection. Contraindications. BYETTA is contraindicated in. Exenatide (Byetta) is the first in a new class of incretin peptide mimetics .. Available at ; accessed October 15, 3. Meneilly. Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) medication, belonging to the group of incretin.

Author: Moogushura JoJogal
Country: Luxembourg
Language: English (Spanish)
Genre: Marketing
Published (Last): 7 November 2009
Pages: 199
PDF File Size: 2.10 Mb
ePub File Size: 17.67 Mb
ISBN: 473-1-22943-938-5
Downloads: 12713
Price: Free* [*Free Regsitration Required]
Uploader: Fauzragore

Following SC administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2. The data available for exenatide showed less of a risk towards thyroid cancer than liraglutide, but to better quantify the risk the FDA has required Amylin to conduct additional rodent studies to better identify the thyroid issue.

Acetaminophen AUC, C max and T max were not significantly bhetta when acetaminophen was given 1 hour before Byetta injection.

Tell your healthcare provider if you have or had kidney problems or a kidney transplant. Patients assigned to placebo received placebo BID throughout the study. Staying Active Learn how regular physical activity can help you manage type 2 diabetes.

Byetta – FDA prescribing information, side effects and uses

Medicines are sometimes prescribed for purposes other than those listed in a Medication Bytta. Oral anti-diabetic drugsinsulins and insulin analogsand other drugs used in diabetes A Retrieved 21 April Exenatide exposure AUC increased proportionally over the therapeutic dose range of 5 to 10 mcg.


The site you are about to visit is maintained by a third party who is byrtta responsible for its contents. Byetta is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. Pharmacokinetics of exenatide was studied in subjects with normal, mild, or moderate renal impairment and subjects with end-stage renal disease.

Welcome to BYETTA.com!

All other trademarks are property of their respective owners. Patients treated with Byetta should be informed of the potential risk for worsening renal function and informed about associated signs and symptoms of renal dysfunction, as well as the possibility of dialysis as a medical intervention if renal failure occurs [see Warnings and Precautions 5.

DeFronzo et al compared exenatide in type 2 diabetic patients being treated with metformin monotherapy in byettz multi-centered, randomized, triple-blinded, placebo-controlled study 6. Patients may develop antibodies to exenatide following treatment with Byetta. Inflammation of the pancreas pancreatitis may happen, which may be severe and lead to death.

Exenatide – Wikipedia

Food and Drug Administration. Byetta has acute effects on pancreatic beta-cell responsiveness to glucose leading to insulin release predominantly in the presence of elevated glucose concentrations. Each pen contains 60 doses. Patients were between the ages of 19 and 78 years, with a mean age of Byetta is a registered trademark of the AstraZeneca group of companies.


Byetta exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies 14 ]. Patients byegta be advised which needle length and gauge should be used.

Add BYETTA to insulin glargine as a complementary action to help improve glycemic control

The effect of Byetta on OC pharmacokinetics is confounded by the possible food effect on OC in this study.

Insulin-like factor 3 Relaxin 123 Serelaxin. Melanin concentrating hormone Antagonists: However, in subjects with end-stage renal disease receiving dialysis, mean exenatide exposure increased by 3.

Population pharmacokinetic analysis of male and female patients suggests that gender does not byetga the distribution and elimination of exenatide.

To report drug exposure during pregnancy call No placebo-treated patients withdrew due to nausea or vomiting. Specifically, fetuses from pregnant rabbits given SC doses of 0.

Byetta was studied in patients 65 years of age or older and in 16 patients 75 years of age or older.

The most frequently reported adverse reaction associated with Byetta, nausea, occurred in a dose-dependent fashion. Nausea, vomiting, and diarrhea were the most common adverse events reported with exenatide therapy.